Imfinzi approved in Japan for Stage III nsclc
02 July 2018 07:00 BST Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer Imfinzi is the only immunotherapy approved for unresectable Stage III NSCLC Approval is based on the Phase III PACIFIC trial AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the Japanese Ministry of Health, Labour and Welfare approved Imfinzi (durvalumab) as maintenance therapy after definitive chemoradiation therapy (CRT) in locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC). Dave Fredrickson,